Related Experiment Video
Updated: Jun 21, 2025
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Locally advanced and metastatic endometrial cancer: Current and emerging therapies
Alixe Salmon1, Alizée Lebeau2, Sylvie Streel1
1Department of Medical Oncology, CHU Liège, Liège, Belgium.
Abstract:
Until recently, patients diagnosed with locally advanced and metastatic endometrial cancer faced significant challenges in their treatment due to limited options and poor prognostic outcomes. The sequencing of tumors has been a major advancement in its management. It has led to The Cancer Genome Atlas classification currently used in clinical practice and the initiation of several clinical trials for innovative treatments targeting principally signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism. Numerous clinical trials are investigating a combinatorial approach of these targeted therapies to counter tumoral resistance, cellular compensatory mechanisms, and tumor polyclonality. This review provides a comprehensive overview of historical, current, and promising therapies in advanced and metastatic endometrial cancer. It particularly highlights clinical research on targeted and hormonal therapies, but also immunotherapy, reflecting the evolving landscape of treatment modalities for this disease.
Insights
Advanced and metastatic endometrial cancer treatment has improved with tumor sequencing, leading to new targeted therapies and clinical trials. This review covers current and future treatment options, including immunotherapy.
Area of Science:
- Oncology
- Genomics
- Translational Medicine
Background:
- Locally advanced and metastatic endometrial cancer historically had limited treatment options and poor prognoses.
- Tumor sequencing has revolutionized management, enabling The Cancer Genome Atlas (TCGA) classification.
- This classification drives clinical trials for novel targeted therapies.
Purpose of the Study:
- To provide a comprehensive overview of historical, current, and emerging therapies for advanced and metastatic endometrial cancer.
- To highlight clinical research in targeted, hormonal, and immunotherapies.
- To reflect the evolving treatment landscape for this disease.
Main Methods:
- Review of historical data and current clinical trial research.
- Analysis of targeted therapies focusing on signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism.
- Inclusion of immunotherapy and combinatorial treatment strategies.
Main Results:
- Tumor sequencing has led to significant advancements in understanding and classifying endometrial cancer.
- Numerous clinical trials are exploring innovative targeted therapies, often in combination.
- Immunotherapy is emerging as a key treatment modality.
Conclusions:
- The treatment paradigm for advanced and metastatic endometrial cancer is rapidly evolving.
- Targeted therapies, hormonal treatments, and immunotherapy offer new hope and improved outcomes.
- Combinatorial approaches are crucial for overcoming treatment resistance and improving patient prognosis.
More Related Videos
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:38Mitogens and the Cell Cycle
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...